Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

D Lorusso; Maria Gabriella Ferrandina; S Pignata; Manuela Ludovisi; R Viganò; S Scalone; P Scollo; E Breda; A Pietragalla; Giovanni Scambia

doi:10.1093/annonc/mdp266

Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

D Lorusso
, Maria Gabriella Ferrandina
, S Pignata
, Manuela Ludovisi
, R Viganò
, S Scalone
, P Scollo
, E Breda
, A Pietragalla
, Giovanni Scambia

Research output: Contribution to journal › Article

33 Citations (Scopus)

Abstract

The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.

Original language	English
Pages (from-to)	61-66
Number of pages	6
Journal	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume	21
DOIs	https://doi.org/10.1093/annonc/mdp266
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma
Disease-Free Survival
Female
Glutamates
Guanine
Humans
Middle Aged
Neoplasm Recurrence, Local
Uterine Cervical Neoplasms

Access to Document

10.1093/annonc/mdp266

Fingerprint

Dive into the research topics of 'Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group'. Together they form a unique fingerprint.

Cite this

Lorusso, D., Ferrandina, M. G., Pignata, S., Ludovisi, M., Viganò, R., Scalone, S., Scollo, P., Breda, E., Pietragalla, A., & Scambia, G. (2010). Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 21, 61-66. https://doi.org/10.1093/annonc/mdp266

Lorusso, D ; Ferrandina, Maria Gabriella ; Pignata, S et al. / Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010 ; Vol. 21. pp. 61-66.

@article{880bd7c656654ad88f932672717e0324,

title = "Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group",

abstract = "The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Disease-Free Survival, Female, Glutamates, Guanine, Humans, Middle Aged, Neoplasm Recurrence, Local, Uterine Cervical Neoplasms, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Disease-Free Survival, Female, Glutamates, Guanine, Humans, Middle Aged, Neoplasm Recurrence, Local, Uterine Cervical Neoplasms",

author = "D Lorusso and Ferrandina, \{Maria Gabriella\} and S Pignata and Manuela Ludovisi and R Vigan{\`o} and S Scalone and P Scollo and E Breda and A Pietragalla and Giovanni Scambia",

year = "2010",

doi = "10.1093/annonc/mdp266",

language = "English",

volume = "21",

pages = "61--66",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

}

Lorusso, D, Ferrandina, MG, Pignata, S, Ludovisi, M, Viganò, R, Scalone, S, Scollo, P, Breda, E, Pietragalla, A & Scambia, G 2010, 'Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol. 21, pp. 61-66. https://doi.org/10.1093/annonc/mdp266

Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. / Lorusso, D; Ferrandina, Maria Gabriella; Pignata, S et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Vol. 21, 2010, p. 61-66.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

AU - Lorusso, D

AU - Ferrandina, Maria Gabriella

AU - Pignata, S

AU - Ludovisi, Manuela

AU - Viganò, R

AU - Scalone, S

AU - Scollo, P

AU - Breda, E

AU - Pietragalla, A

AU - Scambia, Giovanni

PY - 2010

Y1 - 2010

N2 - The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.

AB - The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Carcinoma

KW - Disease-Free Survival

KW - Female

KW - Glutamates

KW - Guanine

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Uterine Cervical Neoplasms

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Carcinoma

KW - Disease-Free Survival

KW - Female

KW - Glutamates

KW - Guanine

KW - Humans

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Uterine Cervical Neoplasms

UR - http://hdl.handle.net/10807/32517

U2 - 10.1093/annonc/mdp266

DO - 10.1093/annonc/mdp266

M3 - Article

VL - 21

SP - 61

EP - 66

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

ER -

Lorusso D, Ferrandina MG, Pignata S, Ludovisi M, Viganò R, Scalone S et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21:61-66. doi: 10.1093/annonc/mdp266

Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this